Navigation Links
Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
Date:2/26/2013

CHAPEL HILL, N.C., Feb. 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes , Ph.D., president and chief executive officer of Cempra, will present at the Cowen and Company 33rd Annual Health Care Conference at 2:10 p.m. EST, Monday, March 4, at the Boston Marriott Copley Place in Boston. Dr. Fernandes will provide an update of the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ (CEM-102 or fusidic acid) for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

About Cempra, Inc. 
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ in Phase 2 for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor and Media Contacts:

Robert E. Flamm , Ph.D.
Russo Partners, LLC 
(212) 845-4226  
Robert.flamm@russopartnersllc.com

Andreas Maratho
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
2. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
3. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
4. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
5. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
6. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
9. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
10. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
11. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Reportlinker.com announces that a new market ... North America Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic Lasers ... Summary GlobalData,s new report, "North America Aesthetic ... provides key market data on the North America ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Laboratories, Safety and Compliance Services Industry ... and Revenue Forecasts to 2021, NAIC ... .html Testing Laboratories, ...
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... to 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Market Outlook to 2020 Summary GlobalData,s ... Market Outlook to 2020", provides key market data ...
Breaking Medicine Technology:North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9
... March 30 A new study, published in the ... of as little as 8 grams (1/3 ounce) of ... body fat percentage, serum total cholesterol, and fasting blood ... grams of "Sun Chlorella A" tablets each morning and ...
... phase III trial -SOUTH SAN FRANCISCO, Calif., March 30 ... their phase II study of HPN-100 for the treatment ... on March 27th at the 16th Annual Clinical Genetics ... Brendan Lee, M.D., Ph.D., Howard Hughes Medical Institute Investigator ...
Cached Medicine Technology:First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4
(Date:8/29/2014)... Delhi, India (PRWEB) August 29, 2014 RBS ... named Remove Scam Book. The service is to help ... negative reviews against them on Scam Book. The service would ... results and make Scam Book complaints fully invisible on Google. ... the service. , On being asked how company can ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A home should be ... up if unaddressed. That’s why Amica Insurance is sharing some tips ... Safety Council suggests taking the following safety measures: , Kitchen, ... – in their original containers, and keep them away from food. ... wall bracket near an exit. , Bathroom , ...
(Date:8/29/2014)... across the Arabian Peninsula and spread to Europe several ... of several hundred people since its discovery in 2012. ... how easily the pathogen spreads from human to human. ... the University of Bonn have now come to the ... transmission is low. Still, a third of infected persons ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks ... throughout the month of September. This special offer features 10 ... of Juvederm. Patients can take advantage of this special offer ... Botox experts will work with patients to determine if Botox ... is Botox? , Botox is a treatment made from ...
(Date:8/29/2014)... VHA Central Atlantic recognized Novant ... care, honoring nine facilities for meeting or exceeding national ... Novant Health, providing quality, affordable healthcare for our communities ... MD, executive vice president and chief medical officer. “These ... experience for each and every one of our patients.” ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
... Poster Presented at Annual Meeting of the American Academy of ... ... 11 NeoStrata today released new,clinical research that validates the benefits ... as a complement to,medical anti-aging treatments such as lasers and microdermabrasion. ...
... research from the UC Davis M.I.N.D. Institute and Center ... the blood of mothers of children with autism bind ... The study authors also found that the reaction was ... form of autism, which occurs when a period of ...
... Deerfield Spa is pleased,to announce the appointment of ... Science., "Jeanine brings outstanding credentials to Deerfield,s ... experience enable her,to fine tune our offerings so ... regimen at the spa, but also learn skills ...
... MyClyns(TM) - the Only Non-Alcohol Product that can be ... Sprayed Directly into the ... today that its revolutionary new product for use after a,potential pathogenic ... upgraded its web site, added a customer,service center and deployed regional ...
... New Patent Expands Geographic Coverage, ... Inc. (OTC Bulletin Board: CARN) today ... granted patent application No. 200600484, titled,"Delivery ... Comprising Anionic,Polysaccharides," relating to the Company,s ...
... University of Oregon scientists say they,ve discovered a ... birth defect in humans that has challenged medical ... zebrafish are present in humans and other vertebrates. ... 10-member research team isolated a disruption in early ...
Cached Medicine News:Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 3Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 4Health News:Deerfield Spa Appoints New Fitness Director 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 3Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 3Health News:Oregon researchers discover a mechanism leading to cleft palate 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: